Leachon appointed DOH ‘special adviser’ | Inquirer

Leachon appointed DOH ‘special adviser’

/ 05:12 AM August 12, 2023

Dr Tony Leachon is named DOH Special Adviser for Non-Communicable Diseases

Tony Leachon. SCREENGRAB from Dr. Tony Leachon’s Facebook page

Former public health consultant to the government Dr. Tony Leachon has been named special adviser of the Department of Health (DOH) for noncommunicable diseases, the DOH said in a statement on Friday. Health Secretary Teodoro Herbosa appointed Leachon, an internist and cardiologist at the Manila Doctors Hospital, who served as adviser of the National Task Force Against COVID-19 at the height of the pandemic during the Duterte administration. According to Herbosa, Leachon’s new role at the DOH would be “beneficial” as he has “exemplary knowledge and experience in the medical field.” Leachon previously served as president of the Philippine College of Physicians and was named one of The Outstanding Filipino Physicians in 2008 and an Outstanding Filipino Awardee in Medicine in 2010. “It’s about time to work together to meet the huge challenges in health care,” said Leachon in a Twitter post. “I hope that some of my ideas and plans will be helpful to reduce the burden of noncommunicable diseases in the Philippines.” —Kathleen de Villa

RELATED STORIES

Dr Tony Leachon named DOH ‘special adviser’

DOH says it’s not endorsing any specific brand of drug for diabetes

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

MOST READ
www
business
www
globalnation
sports
TAGS: DoH, Dr. Tony Leachon

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.